Morgan Stanley Starts Syndax Pharmaceuticals (SNDX) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/17/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Nike out of World Cup contention as Adidas-outfitted teams head to final
- Personalis (PSNL) explores potential sale after interest from Merck and others - source
JMP Securities Starts Syndax Pharmaceuticals (SNDX) at Market Outperform
March 28, 2016 8:36 AM EDTJMP Securities initiated coverage on Syndax Pharmaceuticals (NASDAQ: SNDX) with a Market Outperform rating and a price target of $28.00.
For an analyst ratings summary and ratings history on Syndax Pharmaceuticals click here. For more ratings news on Syndax Pharmaceuticals click here.
Shares of Syndax Pharmaceuticals closed at $12.62 yesterday.
... More